ANIP Q2 2017 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q2 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$45M+42.8% YoY

Gross Profit

$24M52.8% margin

Operating Income

$7M15.6% margin

Net Income

$3M5.9% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

+22.2%

Cash Flow

Operating Cash Flow

$1,000

Free Cash Flow

-$2M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$359M

Total Liabilities

$183M

Stockholders' Equity

$177M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$31M	+42.8%
Gross Profit	$24M	$20M	+21.0%
Operating Income	$7M	$5M	+34.7%
Net Income	$3M	$1M	+138.2%

Revenue Segments

Unapproved Products

$7M100%